TapewireFind a company

person · Reporting owner

Dowden Nathan J

Disclosed activity across 1 company

Tapewire entity
2170
SEC CIK
0001873392

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Entrada Therapeutics, Inc.TRDA · Entity 2163President & COOSeptember 02, 2026September 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Entrada Therapeutics, Inc.

Report date September 02, 2026 · Filed September 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect196,060 Reported balance After 2026-09-02 transaction · row 1
1 source row

Row 1 · 2026-09-02 · Tax withholding · Disposed 2,528 · Balance 196,060

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 02, 2026 Filed Sep 3, 2026 21:18 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 2,528 $7.14 $18,059.78
Disclosure

SEC source: 0001873392-26-000006 · wk-form4_1788470291.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,060

F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 04, 2026 Filed May 4, 2026 23:24 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Exercise / conversionStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001873392-26-000004 · wk-form4_1777937054.xml · derivative · entry 3

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,831

Underlying: Common Stock · 15,000 shares

Expires 2029-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.

F3 · derivative.exercise_date: The shares subject to this option fully vested on November 4, 2023.

Read SEC document
May 04, 2026 Filed May 4, 2026 23:24 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 15,000 $15.33 $229,953.00
Disclosure

SEC source: 0001873392-26-000004 · wk-form4_1777937054.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 198,588

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 04, 2026 Filed May 4, 2026 23:24 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Exercise / conversionCommon Stock 15,000 $1.74 $26,100.00
Disclosure

SEC source: 0001873392-26-000004 · wk-form4_1777937054.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 213,588

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.

Read SEC document
March 10, 2026 Filed Mar 11, 2026 20:35 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 11,894 $13.05 $155,188.15
Disclosure

SEC source: 0001873392-26-000002 · wk-form4_1773261310.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 198,588

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 09, 2026 Filed Mar 11, 2026 20:35 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 3,116 $13.02 $40,582.78
Disclosure

SEC source: 0001873392-26-000002 · wk-form4_1773261310.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 210,482

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 03, 2026 Filed Mar 3, 2026 23:19 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 14,038 $11.76 $165,036.34
Disclosure

SEC source: 0001873392-26-000001 · wk-form4_1772579989.xml · nonDerivative · entry 3

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,598

F2 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 02, 2026 Filed Mar 3, 2026 23:19 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 7,223 $11.66 $84,205.01
Disclosure

SEC source: 0001873392-26-000001 · wk-form4_1772579989.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,636

F2 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 23:19 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantStock Option (Right to Buy) · Derivative 83,200 $0.00 Strike: $11.93 $0.00
Disclosure

SEC source: 0001873392-26-000001 · wk-form4_1772579989.xml · derivative · entry 4

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,200

Underlying: Common Stock · 83,200 shares

Expires 2036-03-01

F5 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 23:19 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantCommon Stock 55,800 $0.00 $0.00
Disclosure

SEC source: 0001873392-26-000001 · wk-form4_1772579989.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 234,859

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

Read SEC document
September 02, 2025 Filed Sep 4, 2025 21:03 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 1,746 $5.43 $9,481.13
Disclosure

SEC source: 0001873392-25-000003 · wk-form4_1757019821.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,059

F1 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 03, 2025 Filed Mar 4, 2025 21:59 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 5,144 $11.68 $60,074.72
Disclosure

SEC source: 0001689375-25-000013 · wk-form4_1741125544.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,805

F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.30 to $11.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 21:59 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantStock Option (Right to Buy) · Derivative 90,800 $0.00 Strike: $11.94 $0.00
Disclosure

SEC source: 0001689375-25-000013 · wk-form4_1741125544.xml · derivative · entry 3

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,800

Underlying: Common Stock · 90,800 shares

Expires 2035-03-01

F4 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2029.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 21:59 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantCommon Stock 60,800 $0.00 $0.00
Disclosure

SEC source: 0001689375-25-000013 · wk-form4_1741125544.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,949

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2026; (ii) 25% on March 1, 2027; (iii) 25% on March 1, 2028 and (iv) the remaining 25% on March 1, 2029, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

Read SEC document
September 26, 2024 Filed Sep 30, 2024 20:32 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 847 $16.00 $13,552.00
Disclosure

SEC source: 0001689375-24-000056 · wk-form4_1727728325.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,149

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024.

Read SEC document
September 09, 2024 Filed Sep 10, 2024 20:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 1,904 $15.07 $28,690.23
Disclosure

SEC source: 0001689375-24-000054 · wk-form4_1726000407.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,996

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 06, 2024 Filed Sep 10, 2024 20:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 399 $15.19 $6,062.69
Disclosure

SEC source: 0001689375-24-000054 · wk-form4_1726000407.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 127,900

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.07 to $15.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 05, 2024 Filed Sep 5, 2024 22:48 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 171 $15.13 $2,586.55
Disclosure

SEC source: 0001689375-24-000051 · wk-form4_1725576514.xml · nonDerivative · entry 5

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,299

F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 04, 2024 Filed Sep 5, 2024 22:48 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 983 $15.42 $15,161.20
Disclosure

SEC source: 0001689375-24-000051 · wk-form4_1725576514.xml · nonDerivative · entry 4

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,470

F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.04 to $15.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 22:48 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 15 $17.70 $265.53
Disclosure

SEC source: 0001689375-24-000051 · wk-form4_1725576514.xml · nonDerivative · entry 3

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,453

F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 22:48 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 156 $16.93 $2,640.38
Disclosure

SEC source: 0001689375-24-000051 · wk-form4_1725576514.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,468

F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.49 to $17.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 03, 2024 Filed Sep 5, 2024 22:48 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 483 $15.76 $7,612.61
Disclosure

SEC source: 0001689375-24-000051 · wk-form4_1725576514.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,624

F1 · shares: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The sale does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.49 to $16.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 20:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Exercise / conversionStock Option (Right to Buy) · Derivative 20,000 $0.00 Strike: $1.74 $0.00
Disclosure

SEC source: 0001689375-24-000048 · wk-form4_1724186017.xml · derivative · entry 4

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,831

Underlying: Common Stock · 20,000 shares

Expires 2029-12-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024.

F4 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on November 4, 2020, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 20:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 502 $16.70 $8,382.40
Disclosure

SEC source: 0001689375-24-000048 · wk-form4_1724186017.xml · nonDerivative · entry 3

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,107

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.69 to $16.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 20:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 26,595 $16.26 $432,418.74
Disclosure

SEC source: 0001689375-24-000048 · wk-form4_1724186017.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,609

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.67 to $16.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 16, 2024 Filed Aug 20, 2024 20:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Exercise / conversionCommon Stock 20,000 $1.74 $34,800.00
Disclosure

SEC source: 0001689375-24-000048 · wk-form4_1724186017.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 157,204

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2024.

Read SEC document
March 06, 2024 Filed Mar 8, 2024 21:34 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 1,826 $12.32 $22,498.69
Disclosure

SEC source: 0001689375-24-000007 · wk-form4_1709933649.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 137,204

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.02 to $12.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 05, 2024 Filed Mar 6, 2024 00:46 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 1,486 $12.28 $18,246.30
Disclosure

SEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · nonDerivative · entry 5

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,030

F3 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 04, 2024 Filed Mar 6, 2024 00:46 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 409 $13.37 $5,467.23
Disclosure

SEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · nonDerivative · entry 4

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,516

F3 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 04, 2024 Filed Mar 6, 2024 00:46 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 343 $12.42 $4,261.09
Disclosure

SEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · nonDerivative · entry 3

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,925

F3 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $13.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 00:46 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantStock Option (Right to Buy) · Derivative 50,100 $0.00 Strike: $13.73 $0.00
Disclosure

SEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · derivative · entry 6

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,100

Underlying: Common Stock · 50,100 shares

Expires 2034-03-01

F7 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2028.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 00:46 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantCommon Stock 60,000 $0.00 $0.00
Disclosure

SEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,268

F2 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 50% on March 1, 2026 and (ii) the remaining 50% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F2 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 50% on March 1, 2026 and (ii) the remaining 50% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 00:46 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantCommon Stock 33,100 $0.00 $0.00
Disclosure

SEC source: 0001689375-24-000004 · wk-form4_1709685952.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,268

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2025; (ii) 25% on March 1, 2026; (iii) 25% on March 1, 2027 and (iv) the remaining 25% on March 1, 2028, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

Read SEC document
September 06, 2023 Filed Sep 6, 2023 21:07 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 59 $14.01 $826.41
Disclosure

SEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 4

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,168

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 06, 2023 Filed Sep 6, 2023 21:07 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 913 $13.43 $12,262.69
Disclosure

SEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 3

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,227

F3 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.88 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
September 05, 2023 Filed Sep 6, 2023 21:07 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 436 $14.46 $6,305.65
Disclosure

SEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,140

F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 21:07 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantStock Option (Right to Buy) · Derivative 21,500 $0.00 Strike: $15.41 $0.00
Disclosure

SEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · derivative · entry 5

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,500

Underlying: Common Stock · 21,500 shares

Expires 2033-09-01

F6 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 21:07 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantCommon Stock 14,200 $0.00 $0.00
Disclosure

SEC source: 0001689375-23-000061 · wf-form4_169403443743456.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,576

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

Read SEC document
July 11, 2023 Filed Jul 12, 2023 20:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 3,897 $18.05 $70,333.06
Disclosure

SEC source: 0001689375-23-000047 · wf-form4_168919399033901.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,376

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 10, 2023 Filed Jul 12, 2023 20:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 3,200 $18.00 $57,605.12
Disclosure

SEC source: 0001689375-23-000047 · wf-form4_168919399033901.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,273

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 22, 2023 Filed Jun 22, 2023 20:46 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 7,097 $16.02 $113,699.62
Disclosure

SEC source: 0001689375-23-000042 · wf-form4_168746675476462.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,473

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 20, 2023 Filed Jun 22, 2023 20:46 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 8,885 $14.94 $132,703.69
Disclosure

SEC source: 0001689375-23-000042 · wf-form4_168746675476462.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,570

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.43 to $15.0090, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 02, 2023 Filed Mar 3, 2023 21:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 Tax withholdingCommon Stock 1,028 $11.60 $11,920.89
Disclosure

SEC source: 0001689375-23-000012 · wf-form4_167787916889742.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,655

F2 · shares: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantStock Option (Right to Buy) · Derivative 43,000 $0.00 Strike: $12.25 $0.00
Disclosure

SEC source: 0001689375-23-000012 · wf-form4_167787916889742.xml · derivative · entry 3

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,000

Underlying: Common Stock · 43,000 shares

Expires 2033-03-01

F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:33 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantCommon Stock 28,400 $0.00 $0.00
Disclosure

SEC source: 0001689375-23-000012 · wf-form4_167787916889742.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,683

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

Read SEC document
March 01, 2023 Filed Apr 19, 2023 21:46 UTC Amendment Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantStock Option (Right to Buy) · Derivative 21,500 $0.00 Strike: $12.25 $0.00
Disclosure

SEC source: 0001689375-23-000026 · wf-form4a_168194078070459.xml · derivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,500

Underlying: Common Stock · 21,500 shares

Expires 2033-03-01

F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027.

F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively.

Read SEC document
March 01, 2023 Filed Apr 19, 2023 21:46 UTC Amendment Entrada Therapeutics, Inc. TRDA · Entity 2163 GrantCommon Stock 14,200 $0.00 $0.00
Disclosure

SEC source: 0001689375-23-000026 · wf-form4a_168194078070459.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,455

F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

F2 · balance_after: The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively.

Read SEC document
October 31, 2022 Filed Nov 2, 2022 20:54 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 2,100 $24.05 $50,495.13
Disclosure

SEC source: 0001689375-22-000040 · wf-form4_166742245826942.xml · nonDerivative · entry 1

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 25, 2022 Filed Oct 27, 2022 22:48 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 900 $21.85 $19,668.96
Disclosure

SEC source: 0001689375-22-000038 · wf-form4_166691086621050.xml · nonDerivative · entry 3

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,383

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.66 to $22.14 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 25, 2022 Filed Oct 27, 2022 22:48 UTC Entrada Therapeutics, Inc. TRDA · Entity 2163 SaleCommon Stock 5,414 $20.97 $113,525.62
Disclosure

SEC source: 0001689375-22-000038 · wf-form4_166691086621050.xml · nonDerivative · entry 2

Dowden Nathan J · CIK 0001873392 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,283

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 to $21.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.